Dinotefuran/Pyriproxyfen/Permethrin

Verify with FDA CVM →

22 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
22
Total Reports
2
Deaths Reported
910.0%
Death Rate

Active Ingredients

Dinotefuran/Pyriproxyfen/Permethrin

Administration Routes

TopicalUnknown

Species Affected

Dog 22

Most Affected Breeds

Bulldog 3
Chihuahua 2
Terrier - Boston 2
Collie - Border 2
Retriever - Golden 2
Shih Tzu 2
Terrier - Irish Soft-coated Wheaten 1
Papillon - Spaniel - Continental Toy (with erect ears or with dropped ears (Phaléne)) 1
Terrier - Jack Russell 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 10
Vomiting 5
Other abnormal test result NOS 5
Behavioural disorder NOS 4
Elevated alanine aminotransferase (ALT) 4
Seizure NOS 3
Weight loss 3
Ataxia 2
Inappropriate urination 2
Emesis 2
Death by euthanasia 2
Inappetence 2

Outcome Breakdown

Recovered/Normal
8 (36.4%)
Outcome Unknown
7 (31.8%)
Ongoing
5 (22.7%)
Euthanized
2 (9.1%)

Data Summary

Metric Value
Total adverse event reports 22
Reports involving death 2
Case-fatality rate (reported events) 910.0%
Distinct species in reports 1
Distinct breeds in reports 15
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Dinotefuran/Pyriproxyfen/Permethrin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 22 adverse event reports referencing Dinotefuran/Pyriproxyfen/Permethrin, including 2 reports in which the animal died — a 910.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Dinotefuran/Pyriproxyfen/Permethrin. Reported administration routes include Topical, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Dinotefuran/Pyriproxyfen/Permethrin reports are Dog (22 reports), with Dog accounting for the largest share. Within those species, Bulldog (3), Chihuahua (2), Terrier - Boston (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Dinotefuran/Pyriproxyfen/Permethrin are Lethargy (see also Central nervous system depression in 'Neurological') (10), Vomiting (5), Other abnormal test result NOS (5), Behavioural disorder NOS (4). Of the 22 reports with a coded outcome, Recovered/Normal is the leading category at 36.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Dinotefuran/Pyriproxyfen/Permethrin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial